{"id":29809,"date":"2024-10-02T09:51:36","date_gmt":"2024-10-02T13:51:36","guid":{"rendered":"https:\/\/genomequebec.com\/?p=29809"},"modified":"2024-10-02T09:52:54","modified_gmt":"2024-10-02T13:52:54","slug":"genome-quebec-invests-up-to-500000-to-boost-rna-therapeutics-innovation-in-quebec","status":"publish","type":"post","link":"https:\/\/genomequebec.com\/en\/news-and-publications\/genome-quebec-invests-up-to-500000-to-boost-rna-therapeutics-innovation-in-quebec\/","title":{"rendered":"G\u00e9nome Qu\u00e9bec invests up to $500,000 to boost RNA therapeutics innovation in Quebec"},"content":{"rendered":"\n

Montreal \u2013 October 2, 2024 – G\u00e9nome Qu\u00e9bec, a private, non-profit organization dedicated to advancing genomics research and innovation in Quebec, is investing up to $500,000 in McGill University\u2019s D2R Initiative. This investment will advance the commercialization of innovative genomic technologies in Quebec through D2R\u2019s Commercialization Priming<\/em> funding program. <\/p>\n\n\n\n

D2R\u2019s Commercialization Priming<\/em> funding program is designed to attract industry partners and investors while advancing  genomic-based RNA therapeutic research. It  provides short-term financial support to researchers to help test and validate the commercial potential of concepts, technologies, or inventions aligned with D2R priority areas: rare diseases, infectious diseases and oncology.<\/p>\n\n\n\n

The Commercialization Priming <\/em>program is part of a suite of D2R funding programs that support interdisciplinary research in line with D2R\u2019s vision of delivering revolutionary genomic-based RNA therapies for all. D2R is supported by the Canada First Research Excellence Fund, as well as additional support from the Quebec Government and other philanthropic and industry partners.<\/p>\n\n\n\n

\u201cMcGill\u2019s D2R initiative is contributing significantly to advancing transformative genomics-based RNA research in the province,\u201d said Dominique B\u00e9rub\u00e9, Vice-President, Research and Innovation at McGill University<\/strong>. \u201cThis investment from G\u00e9nome Qu\u00e9bec provides the vital support researchers and industry partners need for the development and biomanufacturing of novel therapeutics. We look forward to the innovations that will result from this collaboration.\u201d<\/p>\n\n\n\n

 \u201cWe are thrilled to partner with D2R to accelerate genomics research applications and foster innovation in Quebec. By supporting D2R\u2019s Commercialization Priming<\/em> funding program, we aim to de-risk transformative genomic-based RNA therapeutics and capitalize on the province’s strengths in genomics.\u201d St\u00e9phanie Lord-Fontaine, Vice President, Scientific Affairs, G\u00e9nome Qu\u00e9bec<\/strong>.<\/p>\n\n\n\n

G\u00e9nome Qu\u00e9bec\u2019s investment to D2R shows their commitment to enhancing Quebec\u2019s position as a leader in RNA-based therapies. This commitment is further demonstrated through their active involvement in AReNA, a new RNA hub recently announced by the government of Quebec, which brings together key players in life sciences, including D2R and G\u00e9nome Qu\u00e9bec, to bring Quebec to the forefront of innovation in RNA therapies.<\/p>\n\n\n\n

For more information about D2R and its Commercialization Priming<\/em> funding program, please visit the D2R website.<\/a><\/p>\n\n\n\n

-#-<\/p>\n\n\n\n

Media contact<\/strong><\/p>\n\n\n\n

Emily Cholette
Senior Communications Officer , D2R | DNA to RNA
D2R.comms@mcgill.ca<\/a> \u00a0<\/p>\n\n\n\n

-#-<\/p>\n\n\n\n

About D2R: DNA to RNA, An inclusive Canadian approach to genomic-based RNA therapeutics<\/strong><\/p>\n\n\n\n

McGill University’s groundbreaking research initiative, D2R | DNA to RNA, is committed to advancing genomic-based RNA therapies for those affected by infectious diseases, rare diseases or cancer. With a transformative $165 million investment from the Canada First Research Excellence Fund, alongside support from the Quebec Government, philanthropic donors, and industry partners, D2R will develop revolutionary RNA therapeutics.<\/p>\n\n\n\n

For more details, visit www.mcgill.ca\/dna-to-rna\/<\/a><\/p>\n\n\n\n

About G\u00e9nome Qu\u00e9bec:<\/strong><\/p>\n\n\n\n

G\u00e9nome Qu\u00e9bec\u2019s mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. It is a pillar of the Qu\u00e9bec bioeconomy and contributes to Qu\u00e9bec\u2019s influence and its social and sustainable development. The funds invested by G\u00e9nome Qu\u00e9bec are provided by the minist\u00e8re de l’\u00c9conomie, de l’Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE), the government of Canada, through Genome Canada, and private partners.<\/p>\n\n\n\n

For more details, visit: genomequebec.com\/en\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Montreal \u2013 October 2, 2024 – G\u00e9nome Qu\u00e9bec, a private, non-profit organization dedicated to advancing genomics research and innovation in Quebec, is investing up to $500,000 in McGill University\u2019s D2R…<\/p>\n","protected":false},"author":2,"featured_media":29811,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"16663,29758,16488,16748,16606,16709","_relevanssi_noindex_reason":"","footnotes":""},"categories":[295],"tags":[],"class_list":["post-29809","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/posts\/29809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/comments?post=29809"}],"version-history":[{"count":3,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/posts\/29809\/revisions"}],"predecessor-version":[{"id":29822,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/posts\/29809\/revisions\/29822"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/media\/29811"}],"wp:attachment":[{"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/media?parent=29809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/categories?post=29809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genomequebec.com\/en\/wp-json\/wp\/v2\/tags?post=29809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}